AR071392A1 - Derivados de iminopiridina y su uso - Google Patents

Derivados de iminopiridina y su uso

Info

Publication number
AR071392A1
AR071392A1 ARP090101416A ARP090101416A AR071392A1 AR 071392 A1 AR071392 A1 AR 071392A1 AR P090101416 A ARP090101416 A AR P090101416A AR P090101416 A ARP090101416 A AR P090101416A AR 071392 A1 AR071392 A1 AR 071392A1
Authority
AR
Argentina
Prior art keywords
group
substituent
optionally
chloro
imino
Prior art date
Application number
ARP090101416A
Other languages
English (en)
Inventor
Masato Yoshida
Nobuki Sakauchi
Ayumu Sato
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of AR071392A1 publication Critical patent/AR071392A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente pretende proporcionar un derivado de compuesto de iminopiridina que tiene una accion antagonista del receptor adrenérgico alfa1D, que es util como un agente para la profilaxis o el tratamiento de una enfermedad del tracto urinario inferior y similares. Profármacos, agentes farmacéuticos que los comprenden. Reivindicacion 1: Un compuesto caracterizado por la formula (1) en el cual el anillo A- es un grupo anular aromático que tiene por lo menos un sustituyente R1 y que tiene en forma adicional y opcional sustituyente (s); R1 es un grupo seleccionado de (i) un grupo representado por la formula -S(O)nR3 en el cual R3 es un átomo de hidrogeno, un grupo hidrocarbonado que tiene, en forma opcional, sustituyente(s) o un grupo amino que tiene, en forma opcional, sustituyente(s), y n es un numero entero de 0 hasta 2; (ii) un grupo heterocíclico no aromático que contiene nitrogeno que tiene, en forma opcional, sustituyente(s); (iii) un grupo carbamoilo que tiene, en forma opcional, sustituyente (s); (iv) un grupo amino sustituido por carbamoilo que tiene, en forma opcional, sustituyente(s); (v) un grupo alcoxicarbonilo; y (vi) un grupo alquilo sustituido por hidroxi; y R2 es un átomo de hidrogeno, un átomo de halogeno, un grupo ciano, un grupo hidrocarbonado que tiene, en forma opcional, sustituyente(s), un grupo acilo, un grupo heterocíclico que tiene, en forma opcional, sustituyente(s), un grupo amino que tiene, en forma opcional, sustituyente(s), un grupo hidroxi que tiene, en forma opcional, un sustituyente, o un grupo mercapto que tiene, en forma opcional, un sustituyente; siempre que 5-cloro-1-{4-[(dimetilamino)sulfonil]bencil}-2-imino-1,2-dihidropiridin-3-carboxamida, 5-cloro-1-[3-(1-hidroxi-1-metiletil)bencil]-2-imino-1,2-dihidropiridin-3-carboxamida, metil 3-{[3-(aminocarbonil)-5-cloro-2-iminopiridin-1(2H)-il]metil}benzoato, 1-[3-(aminocarbonil)bencil]-5-cloro-2-imino-1,2-dihidropiridin-3-carboxamida, 5-cloro-1-[4-cloro-2-(metilsulfonil)bencil]-2-imino-1,2-dihidropiridin-3-carboxamida, 5-cloro-2-imino-1-[4-(metilsulfonil)bencil]-1,2-dihidropiridin-3-carboxamida, 5-cloro-2-imino-1-[2-metoxi-5-(metilsulfonil)bencil)-1,2-dihidropiridin-3-carboxamida, 5-cloro-1-[2-cloro-4-(metilsulfonil)bencil]-2-imino-1,2-dihidropiridin-3-carboxamida, 5-cloro-1-{3-cloro-5-[(metilamino)carbonil]bencil}-2-imino-1,2-dihidropiridin-3-carboxamida, 5-cloro-1-[2-cloro-5-(metilsulfonil)bencil]-2-imino-1,2-dihidropiridin-3-carboxamida, 1-[3-(aminocarbonil)-5-clorobencil]-5-cloro-2-imino-1,2-dihidropiridin-3-carboxamida, 5-cloro-2-imino-1-[3-(metilsulfonil)bencil]-1,2-dihidropiridin-3-carboxamida, y 5-cloro-2-imino-1-(3-morfolin-4-ilbencil)-1,2-dihidropiridin-3-carboxamida están excluidos; o una de sus sales. Reivindicacion 6: Un compuesto caracterizado por la formula (2) en el cual el anillo A0- es un grupo anular aromático que tiene por lo menos un sustituyente R10 y que tiene en forma adicional y opcional sustituyente(s); R10 es un grupo seleccionado de (i) un grupo representado por la formula -S(O)nR30 en el cual R30 es un grupo heterocíclico no aromático que contiene nitrogeno que tiene, en forma opcional, sustituyente(s), y n es un numero entero de 0 hasta 4; (ii) un grupo alcoxicarbonilamino; (iii) un grupo alquilsulfonilamino; y (iv) un grupo alquilcarbonilamino; y R20 es un átomo de hidrogeno, un átomo de halogeno, un grupo ciano, un grupo hidrocarbonado que tiene, en forma opcional, sustituyente(s), un grupo acilo, un grupo heterocíclico que tiene, en forma opcional, sustituyente(s), un grupo amino que tiene, en forma opcional, sustituyente(s), un grupo hidroxi que tiene, en forma opcional, un sustituyente, o un grupo mercapto que tiene, en forma opcional, un sustituyente; o una de sus sales.
ARP090101416A 2008-04-23 2009-04-22 Derivados de iminopiridina y su uso AR071392A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008113135 2008-04-23

Publications (1)

Publication Number Publication Date
AR071392A1 true AR071392A1 (es) 2010-06-16

Family

ID=40821652

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090101416A AR071392A1 (es) 2008-04-23 2009-04-22 Derivados de iminopiridina y su uso

Country Status (24)

Country Link
US (2) US20110039846A1 (es)
EP (1) EP2271624B9 (es)
JP (1) JP5462803B2 (es)
KR (1) KR20100130235A (es)
CN (1) CN102066327B (es)
AR (1) AR071392A1 (es)
AU (1) AU2009238938A1 (es)
BR (1) BRPI0910737A2 (es)
CA (1) CA2723216C (es)
CL (1) CL2009000964A1 (es)
CO (1) CO6260091A2 (es)
CR (1) CR11765A (es)
DO (1) DOP2010000321A (es)
EA (1) EA019641B1 (es)
EC (1) ECSP10010626A (es)
ES (1) ES2478823T3 (es)
GE (1) GEP20135883B (es)
IL (1) IL208771A0 (es)
MX (1) MX2010011652A (es)
NZ (1) NZ588909A (es)
PE (1) PE20091784A1 (es)
TW (1) TW200948784A (es)
UY (1) UY31781A (es)
WO (1) WO2009131245A1 (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7982044B2 (en) 2008-04-23 2011-07-19 Takeda Pharmaceutical Company Limited Iminopyridine derivatives and use thereof
US8470859B2 (en) 2006-10-23 2013-06-25 Takeda Pharmaceutical Company Limited Iminopyridine derivative and use thereof

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ588909A (en) * 2008-04-23 2012-08-31 Takeda Pharmaceutical Iminopyridine derivatives and use thereof
US20110039892A1 (en) * 2008-04-23 2011-02-17 Takeda Pharmaceutical Company Limited Iminopyridine derivative and use thereof
RU2014147017A (ru) 2012-04-24 2016-06-10 Чугаи Сейяку Кабусики Кайся Производное бензамида
KR20150003849A (ko) 2012-04-24 2015-01-09 추가이 세이야쿠 가부시키가이샤 퀴나졸린디온 유도체
CN103058913B (zh) * 2012-12-13 2015-09-30 江苏弘和药物研发有限公司 5-氯异吲哚酮的合成方法
AU2014338070A1 (en) 2013-10-23 2016-05-05 Chugai Seiyaku Kabushiki Kaisha Quinazolinone and isoquinolinone derivative
CA2950259C (en) * 2014-05-28 2022-08-23 Astellas Pharma Inc. Pyridine derivative for the treatment of nocturia
CN111217731B (zh) * 2020-02-19 2022-06-03 广东工业大学 一种邻位亚胺酯或氰基取代的芳基硫醚衍生物及制备与应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2540109B1 (fr) * 1983-01-28 1985-08-30 Logeais Labor Jacques Imino-2 pyrrolidines, leur procede de preparation et leurs applications en therapeutique
DE4021439A1 (de) * 1989-12-14 1991-06-20 Bayer Ag 2-iminopyridin-derivate
US5688795A (en) * 1994-11-08 1997-11-18 Syntex (U.S.A.) Inc. 3-(4-phenylpiperazin-1-yl)propyl-amino, thio and oxy!-pyridine, pyrimidine and benzene derivatives as α1 -adrenoceptor antagonists
UA52681C2 (uk) * 1997-04-08 2003-01-15 Янссен Фармацевтика Н.В. Похідні 1,2,3,4-тетрагідро-бензофуро[3,2,-c]піридину, спосіб їх одержання та фармацевтична композиція на їх основі
ZA991315B (en) * 1998-02-20 2000-11-20 Ortho Mcneil Pharm Inc Novel substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia.
US6153614A (en) * 1998-07-16 2000-11-28 Abbott Laboratories Piperazinyl pyrimidine dione compounds selective for adrenoceptors
DE19845202A1 (de) * 1998-10-01 2000-04-06 Wella Ag Haarwuchsmittel
ES2318649T3 (es) * 2000-10-20 2009-05-01 EISAI R&D MANAGEMENT CO., LTD. Procedimiento de preparacion de derivados de 4-fenoxi quinolinas.
FR2825705B1 (fr) * 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
US7375100B2 (en) * 2003-06-04 2008-05-20 Pfizer Inc 2-amino-pyridine derivatives useful for the treatment of diseases
WO2005092840A1 (en) * 2004-03-23 2005-10-06 Pfizer Limited Formamide derivatives useful as adrenoceptor
ES2241496B1 (es) * 2004-04-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridina.
US20050288270A1 (en) * 2004-05-27 2005-12-29 Pfizer Inc New aminopyridine derivatives and their use as pharmaceuticals
TW200700392A (en) * 2005-03-16 2007-01-01 Astrazeneca Ab Novel compounds
ES2303758B1 (es) * 2006-02-20 2009-08-13 Laboratorios Almirall S.A. Nuevos derivados de piridin-3-amina.
EP2077262A4 (en) * 2006-10-23 2011-12-28 Takeda Pharmaceutical IMINOPYRIDINE DERIVATIVES AND THEIR USE
EP2178861B1 (en) * 2007-07-19 2014-08-20 Merck Sharp & Dohme Corp. Heterocyclic amide compounds as protein kinase inhibitors
US8129394B2 (en) * 2008-03-21 2012-03-06 Novartis Ag Heteroaryl-substituted imidazole compounds and uses thereof
NZ588909A (en) * 2008-04-23 2012-08-31 Takeda Pharmaceutical Iminopyridine derivatives and use thereof
US8290250B2 (en) * 2008-12-26 2012-10-16 Five Apes, Inc. Method and apparatus for creating a pattern recognizer

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470859B2 (en) 2006-10-23 2013-06-25 Takeda Pharmaceutical Company Limited Iminopyridine derivative and use thereof
US7982044B2 (en) 2008-04-23 2011-07-19 Takeda Pharmaceutical Company Limited Iminopyridine derivatives and use thereof
US7985862B2 (en) 2008-04-23 2011-07-26 Takeda Pharmaceutical Company Limited Iminopyridine derivatives and use thereof
US7985863B2 (en) 2008-04-23 2011-07-26 Takeda Pharmaceutical Company Limited Iminopyridine derivatives and uses thereof
US8481569B2 (en) 2008-04-23 2013-07-09 Takeda Pharmaceutical Company Limited Iminopyridine derivatives and use thereof

Also Published As

Publication number Publication date
GEP20135883B (en) 2013-07-25
EP2271624B9 (en) 2014-11-12
US20110039846A1 (en) 2011-02-17
CO6260091A2 (es) 2011-03-22
EA019641B1 (ru) 2014-05-30
MX2010011652A (es) 2010-12-06
WO2009131245A1 (en) 2009-10-29
JP5462803B2 (ja) 2014-04-02
TW200948784A (en) 2009-12-01
EP2271624A1 (en) 2011-01-12
JP2011518766A (ja) 2011-06-30
CA2723216C (en) 2017-01-24
BRPI0910737A2 (pt) 2019-09-24
EA201071229A1 (ru) 2011-06-30
CA2723216A1 (en) 2009-10-29
NZ588909A (en) 2012-08-31
DOP2010000321A (es) 2010-11-15
EP2271624B1 (en) 2014-05-21
AU2009238938A1 (en) 2009-10-29
UY31781A (es) 2009-12-14
US20090270393A1 (en) 2009-10-29
CN102066327A (zh) 2011-05-18
CL2009000964A1 (es) 2010-03-26
CN102066327B (zh) 2013-05-29
IL208771A0 (en) 2010-12-30
ECSP10010626A (es) 2011-03-31
KR20100130235A (ko) 2010-12-10
ES2478823T3 (es) 2014-07-23
CR11765A (es) 2010-12-15
PE20091784A1 (es) 2009-12-05

Similar Documents

Publication Publication Date Title
AR071392A1 (es) Derivados de iminopiridina y su uso
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
AR066962A1 (es) Compuesto heterociclico fusionado
DE602006011752D1 (de) Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
UY31127A1 (es) Ligandos de oxiadazol del receptor metabotropico para el glutamato y su utilizacion como potenciadores - 841
CR9078A (es) Derivado de bencimidazol ariloxi-sustituidos
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
ECSP099046A (es) Derivados ciclopropil amina
DK2207770T3 (da) 1, 2, 3-triazolderivater til anvendelse som stearoyl-coa desaturase-inhibitorer
AR049276A1 (es) Compuestos carboxamidos opiodes y composiciones farmaceuticas que los contienen
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten
CL2008001670A1 (es) Compuestos derivados de piperidina o piperazina, inhibidores de dgat1; composicion farmaceutica; combinacion farmaceutica; y uso para la prevencion o tratamiento de enfermedades tales como obesidad, hipercolesterolemia, dislipidemia, entre otras.
DK1926729T3 (da) Benzothiazolcyclobutylaminderivater og deres anvendelse som histamin-3-receptorligander
CL2019000768A1 (es) Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos.
UY31383A1 (es) N-aroil-n??-(6-(opcionalmente sustituido) alquilsulfonibenzotiazol-2-il)ureas
CR11759A (es) Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
UY27018A1 (es) Derivados de la pirimidina
AR057202A1 (es) Derivados de pirimidina para el tratamiento de crecimiento celular anormal
CL2019000727A1 (es) Compuestos de indazol para usar en lesiones de tendones y/o ligamentos.
CL2008003558A1 (es) Composicion farmaceutica que comprende valrubicina y sulfoxido de dimetilo en forma de dosis intravesical, util para tratar cancer a la vejiga.
ES2571793T3 (es) Procedimiento para la síntesis de derivados de 3,6-dihidro-1,3,5-triazina
EA201000611A1 (ru) 4,4-дизамещенные пиперидины
AR085276A1 (es) Antagonistas de p2x7r y su uso
BR112022005723A2 (pt) Compostos de indol carboxamida e seu uso para o tratamento de infecções micobacterianas
EA201000720A1 (ru) 4,4-дизамещённые пиперидины как ингибиторы ренина

Legal Events

Date Code Title Description
FA Abandonment or withdrawal